Wearable EEG monitoring start-up Epitel raises $12.5M to market seizure detection system

Epi­tel rais­es $12.5M for wear­able seizure detec­tion sys­tem (Mobi­Health News): Epi­tel, mak­er of a wear­able elec­troen­cephalo­gram (EEG) sys­tem for seizure detec­tion, announced Wednes­day it had scored $12.5 mil­lion in Series A fund­ing. The round was led by Cat­a­lyst Health Ven­tures (CHV) and Genoa Ven­tures, with par­tic­i­pa­tion from Dex­com, OSF Ven­tures, Wave­mak­er 360, Med­Moun­tain Ven­tures and…

Read More

Digital therapeutics pioneer Akili Interactive plans to go public in mid-2022 at a $1B valuation

Pal­i­hapi­tiya-Led SPAC to Merge With Akili in $1 Bil­lion Deal (Bloomberg): Akili Inter­ac­tive, a start­up that has devel­oped a video game to help treat atten­­tion-deficit dis­or­ders in kids, has agreed to go pub­lic through a merg­er with one of Chamath Palihapitiya’s blank-check com­pa­nies. The deal, which con­firms a Bloomberg News report, val­ues the com­bined entity…

Read More

APA: With digital mental health going mainstream, will/ should psychologists be able to “prescribe” interventions?

Men­tal health, meet ven­ture cap­i­tal (APA): Until recent­ly, men­tal health was a rel­a­tive blip on the radar of ven­ture cap­i­tal­ists. But over the past few years, and par­tic­u­lar­ly since the onset of the COVID-19 pan­dem­ic, pri­vate investors have made a dra­mat­ic run for this space, pour­ing $3.1 bil­lion into men­tal health ven­tures by the third…

Read More

Could I be wrong? Exploring cognitive bias, curiosity, intellectual humility, and lifelong learning

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eight time­ly sci­en­tif­ic and indus­try news plus a few fun teasers to appre­ci­ate our unique human brains. #1. Could I be wrong? Explor­ing research on cog­ni­tive bias, curios­i­ty, intel­lec­tu­al humil­i­ty, and life­long learn­ing “None of us thinks that our beliefs and atti­tudes are incor­rect; if we…

Read More

FDA-approved, Cybin-sponsored clinicial trial to measure ketamine’s impact on the brain via Kernel Flow neuroimaging helmet

Kernel’s Brain-Imag­ing Hel­met Approved For Clin­i­cal Tri­al On Patients Using Ket­a­mine (Forbes): The U.S. Food and Drug Admin­is­tra­tion has approved a clin­i­cal tri­al using a neu­roimag­ing hel­met made by Los Ange­les-based Ker­nel to track what hap­pens in the brain when a human takes a psy­che­del­ic dose of ketamine.

Read More

Study: Fewer than 1% of geriatric patients with cognitive complaints met Aduhelm research trial criteria. What can we expect about its real-world safety?

Bio­gen’s Aduhelm label far exceeds clin­i­cal tri­al pop­u­la­tion, study says. That could bring real-world sur­pris­es (Fierce Phar­ma): While the chat­ter sur­round­ing Biogen’s con­tro­ver­sial Alzheimer’s med Aduhelm has large­ly been cen­tered on a piv­otal Medicare reim­burse­ment deci­sion as of late, ana­lysts are point­ing to one new study that sug­gests there may be “room for sur­pris­es” when…

Read More